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Abstract
Background: Ultiva™ contains the potent short-acting μ-opioid receptor agonist remifentanil hydrochloride, and it
is commonly administered intravenously during general anesthesia. It is not approved for epidural or intrathecal use
in clinical practice because it contains glycine as an acidic buffer. However, at this moment, very limited
information is available on epidural administration of Ultiva™.
Case presentation: We report the accidental administration of 300 μg of remifentanil and 2.25 mg of glycine into
the epidural space after emergence from general anesthesia for distal pancreatectomy and the complete time
course of its consequences. The respiratory depression occurred at 5 min after the administration, and complete
loss of consciousness was observed at 8 min. The patient was re-intubated and underwent mechanical respiration.
At 45 min (33 min after re-intubation), spontaneous respiration resumed, she was responsive to commands, and her
orientation returned. She was extubated successfully.
Conclusions: These consequences might have resulted from the diffusion of the components of Ultiva™ into not
only systemic circulation but also the cerebrospinal fluid. Moreover, the complex pathophysiology might be
associated with remifentanil, as well as glycine present in Ultiva™.
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Background
Ultiva™ is commonly administered intravenously during
general anesthesia, and the principal ingredient is the po-
tent short-acting μ-opioid receptor agonist remifentanil
hydrochloride. Studies in rats have suggested that intra-
thecal administration of remifentanil can induce profound
analgesia [1, 2]. Ultiva™ is not approved for epidural or
intrathecal use in clinical practice because it contains gly-
cine as an acidic buffer. Thus, very limited information is
available on epidural administration of Ultiva™. Here, we
report the accidental administration of 300 μg of remifen-
tanil and 2.25 mg of glycine into the epidural space after
emergence from general anesthesia for distal pancreatec-
tomy and the complete time course of its consequences.
Case presentation
A 67-year-old woman (height, 149 cm; weight, 57 kg) with
pancreatic insulinoma was admitted for laparoscopic
tumor resection. She claimed experiencing intermittent
hypoglycemic attacks due to insulinoma, and therefore,
she was prescribed diazoxide. At the preoperative consult-
ation, she was classified as American Society of Anesthesi-
ologists Physical Status II, and general anesthesia
supplemented by epidural block was scheduled.
Her preoperative blood pressure was 150/90 mmHg,
and her heart rate was 95 beats/min in the supine pos-
ition in the operating room. After placement of the epi-
dural catheter at the Th8–Th9 epidural space, general
anesthesia was induced with propofol (50 mg) and fen-
tanyl (100 μg). Intubation of the trachea was facilitated
with rocuronium. Anesthesia was maintained with 1.25–
1.5 % sevoflurane in air/oxygen and 0.05–0.1 μ/kg/min
* Correspondence: hif1@mac.com
Department of Anesthesiology, Kansai Medical University, 2-3-1 Shinmachi,
Hirakata 573-1191, Japan
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Nishimoto et al. JA Clinical Reports  (2016) 2:19 
DOI 10.1186/s40981-016-0046-5
remifentanil. Additionally, levobupivacaine (0.25 %) was
intermittently administered into the epidural space. The
surgery lasted for 5 h and 7 min and was uneventful.
The estimated blood loss was 377 mL, and a total of
3900 mL of crystalloid fluid was infused during the peri-
operative period. The urine output was 1880 mL. The
patient emerged from anesthesia promptly and was suc-
cessfully extubated. After extubation, she was alert and
fully responsible. Her respiratory rate was 16 breaths/
min, and her SpO2 level was 100 % under 3 L/min O2
insufflation. However, she complained of abdominal
pain, and 3 mL of a solution, which was believed to be
0.25 % levobupivacaine, was administered into the epi-
dural space. At 3 min after administration, her pain sub-
sided; however, the SpO2 level decreased to 95 %. At this
time point, she was alert and responsible and could take
a deep breath in response to a command. At 5 min, the
SpO2 level decreased to 90 %, and her conscious level
reduced to Japan Coma Scale (JCS) 30. At this time
point, it was found that the solution administered was
3 mL of Ultiva™ (100 μg/mL) dissolved in 0.9 % NaCl. At
8 min, her SpO2 level was 93 % and conscious level was
JCS200. She underwent mask ventilation for 5 min; how-
ever, the consciousness level did not improve. At 13 min
after administration, her trachea was intubated, with
100 mg of propofol. A muscle relaxant was not used. Be-
cause spontaneous respiration was not detected after in-
tubation, she underwent mechanical ventilation. At
45 min (33 min after re-intubation), spontaneous respir-
ation resumed, she was responsive to commands, and
her orientation returned. She was extubated successfully
and was transferred to the ward. On assessment, she did
not demonstrate any neurological deficit.
Discussion
We reported the accidental epidural administration of
the potent opioid reagent Ultiva™ and the complete time
course of its consequences.
In our case, the first symptom was a decrease in the
SpO2 level, which was detected 3 min after the epidural
administration of Ultiva™ solution. Intriguingly, at 10 min,
spontaneous respiration was preserved. According a
pharmacokinetics model [3, 4], after intravenous bolus ad-
ministration of 300 μg of remifentanil, the peak whole
blood concentration of remifentanil rapidly reached
33 ng/mL and then the concentration decreased rapidly to
1.53 ng/mL within 15 min and after 30 min the concen-
tration decreased to 0.058 ng/ml. In contrast, the effect
site concentration peaked to 17.2 ng/mL and then
decreased to 2.3 ng/mL within 15 min. Thus, the time
course of our case differs from that of the
pharmacokinetics model. The discrepancy may have been
caused by a delay in the diffusion of remifentanil from the
epidural space to systemic circulation or by diffusion of
remifentanil from the epidural space to the cerebrospinal
fluid. The diffusion of remifentanil from the epidural
space to the cerebrospinal fluid is supported by the fact
that respiratory suppression and consciousness disturb-
ance continued for more than 40 min in our case. These
consequences would have not occurred for such a long
duration if the effects were systemic.
In the present case, we used a 2 mg formulation of
Ultiva™, which contains 15 mg of glycine as an adjunct.
Thus, the consequences might be partly due to the ef-
fects of glycine on the central nervous system, in
addition to the effects of remifentanil. Glycine has been
shown to be not only an inhibitory neurotransmitter but
also an N-methyl-D-aspartate receptor coactivator [5, 6].
A previous study reported that intrathecal administra-
tion of Ultiva™ to substantia gelatinosa neurons hyperpo-
larized the membrane potentials and depressed
presynaptic glutamate release predominantly through
the activation of glycine receptors [7]. Moreover, intra-
thecal glycine was shown to cause reversible motor im-
pairment in a rat model [1].
In this case, we did not use naloxone to antagonize the
effect of remifentanil to alleviate the adverse phenomena
based on the two reasons. We thought that if the dis-
turbance of consciousness and loss of spontaneous
respiration was due to the effect of remifentanil, the
symptoms may disappear soon. However, intravenous
administration of naloxone might be a causal treatment
and have elucidated the etiology of the symptoms.
A previous report presented a case of epidural admin-
istration of 567 μg of remifentanil hydrochloride before
induction of general anesthesia [8]. In that case, the pa-
tient became unconscious and developed rigidity of the
chest and abdominal muscles. General anesthesia was
introduced immediately after the administration, and
therefore, the complete time course of the consequences
was not demonstrated. In contrast, in our case, rigidity
of the chest and abdominal muscles was not observed.
In addition, our case demonstrated the full time course
of respiratory suppression and consciousness disturb-
ance. Therefore, to our knowledge, this is the first report
of the complete time course of the consequences of epi-
dural administration of Ultiva™.
The sole cause of the accident described in this case is
certainly the wrong administration of Ultiva™ solution
into the epidural space. The more intensive attention
should have be paid to “five rights” concept including
right patient, right drug, right dose, right route, and
right time [9]. The differential usage of syringe (e.g., vol-
ume and color) for venous and epidural administration
might have prevented the occurrence of the incident.
In the morning of postoperative day (POD) 1, the
patient was fully alert and responsive. Neither sensory
nor motor neurological disturbance was observed. The
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patient was discharged on foot on POD 15 without fur-
ther complications.
Conclusions
We reported a case of accidental administration of the
remifentanil formulation Ultiva™ into the epidural space.
Complete loss of consciousness and respiratory depres-
sion continued for 45 min. These consequences might
have resulted from the diffusion of the components of
Ultiva™ into not only systemic circulation but also the
cerebrospinal fluid. Moreover, the complex pathophysi-
ology might be associated with remifentanil, as well as
glycine present in Ultiva™.
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